| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fec4337665eedc2ce05fc3a146b0b0ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_338122610c66aec3edaa563d6ecc7b71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_092481bc2b669810889f77bd233ebdd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e73c1436c9da3d456039a665453bbf90 |
| publicationDate |
2021-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113271953-A |
| titleOfInvention |
Combination of cellular immunotherapy |
| abstract |
A method of treating a tumor, characterized by administering to an individual with a tumor immune effector cells that express receptors that recognize tumor antigens and gemcitabine. A kit for treating tumors, characterized in that the kit comprises: 1) immune effector cells expressing receptors recognizing tumor antigens; 2) gemcitabine; 3) for containing the above 1) and 2) a container for the substance; and 4) instructions for administering the kit for treating a tumor. |
| priorityDate |
2019-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |